|
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer Clinical research trials and Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer. Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer clinical trial. Human subjects often get the best healthcare available for their Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer  Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
For Condition: Lymphoma,Multiple Myeloma,Leukemia
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , Jonsson Comprehensive Cancer Center
Synopsis: RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy. PURPOSE: Randomized phase II trial to study the effectiveness of keratinocyte growth factor in preventing oral mucositis in patients who have hematologic cancers and who are undergoing radiation therapy and chemotherapy before autologous peripheral stem cell transplantation.
Details: OBJECTIVES: I. Determine the efficacy of recombinant keratinocyte growth factor in reducing the duration of severe oral mucositis induced by total body irradiation and high dose chemotherapy in patients with hematologic malignancies. II. Determine the incidence and duration of severe oral mucositis, grade 2-4 diarrhea, and febrile neutropenia in these patients. III. Determine the necessity of use of transdermal or parenteral opioid analgesics and IV antifungals or antibiotics for febrile neutropenia or infections in these patients. IV. Determine the quality of life of these patients. PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study. Patients are stratified by center. Patients are randomized to one of three treatment arms. Arm I: Patients receive 7 doses of recombinant human keratinocyte growth factor (rHuKGF). Arm II: Patients receive 4 doses of rHuKGF followed by 3 doses of placebo. Arm III: Patients receive 7 doses of placebo. Patients receive one of two conditioning regimens. Primary conditioning regimen: Patients receive rHuKGF or placebo daily on days -11, -10, -9, -5, 0, 1, and 2. Total body irradiation (TBI) is administered twice a day on days -8 to -5. Patients receive etoposide on day -4, cyclophosphamide IV over 1 hour on day -2, and peripheral blood stem cell transplantation (PBSCT) on day 0. Filgrastim (G-CSF) IV or SC is administered beginning on day 0 and continuing for 21 days or until blood counts recover. Secondary conditioning regimen: Patients receive rHuKGF or placebo daily on days -13, -12, -11, -7, 0, 1, and 2. TBI is administered twice a day on days -10 to -7. Patients receive ifosfamide IV over 1 hour followed by etoposide over 23 hours on days -6 to -2, then PBSCT on day 0. G-CSF IV or SC is administered beginning on day 0 for 21 days or until blood counts recover. Quality of life is assessed daily beginning on day -11 and continuing until day 28. Patients are followed at day 28 and then at day 60-100. PROJECTED ACCRUAL: A minimum of 111 patients (37 per arm) will be accrued for this study.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: 12 Years/65 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosis of Non-Hodgkin's lymphoma, Hodgkin's disease, acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, or multiple myeloma - Eligible for total body irradiation plus high dose chemotherapy followed by autologous peripheral blood stem cell transplantation - At least 1,500,000 CD34+ cells/kg cryopreserved - No prior treatment on this study --Prior/Concurrent Therapy-- - Biologic therapy: No prior bone marrow or peripheral blood stem cell transplantation, unless undergoing second transplant of a tandem transplant regimen, with no complications after first transplant; No concurrent interleukin-11 - Chemotherapy: No other concurrent cytotoxic chemotherapy, except intrathecal methotrexate for CNS involvement - Endocrine therapy: Not specified - Radiotherapy: No prior extensive radiotherapy that would preclude total body irradiation - Surgery: Not specified - Other: At least 30 days since prior investigational devices or drugs, except Baxter Isolex i column; No other concurrent investigational agents; No concurrent prophylactic oral cryotherapy during chemotherapy --Patient Characteristics-- - Age: 12 to 65 - Performance status: Karnofsky 70-100%; SWOG 0 or 1 - Life expectancy: Not specified - Hematopoietic: Absolute neutrophil count greater than 1000/mm3; Platelet count greater than 100,000/mm3; If conditioning regimen scheduled soon after apheresis, platelet count of greater than 50,000/mm3 but less than 100,000/mm3 allowed - Hepatic: Bilirubin no greater than 2 mg/dL - Renal: Creatinine no greater than 2 mg/dL - Cardiovascular: No congestive heart failure; No New York Heart Association class III or IV heart disease - Pulmonary: DLCO at least 50% predicted - Other: No prior or concurrent second malignancy; No active infection or oral mucositis; No insulin dependent diabetes mellitus; HIV negative; No sensitivity to E. coli derived products; Not pregnant or nursing; Fertile patients must use effective contraception one month before, during, and one month after study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
ChristosEmmanouilides, Study Chair, Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Additional Information:
Study ID Numbers: CDR0000067362; UCLA-9812041,NCI-G99-1609,AMGEN-KGF-980231-03
Study Start Date: February 2001
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004132
Other Lymphoma Studies:
1. Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes
2. Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
3. Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers
4. Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
5. Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma
Related Studies:
Other Lymphoma Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
|
|
|
|
|
|
|
|
